FDA Panel to Debate Efficacy, Safety of Pfizer's JAK Inhibitor

Whether Pfizer Inc. cleared the efficacy bar with tofacitinib, its first-in-class JAK inhibitor for rheumatoid arthritis (RA), will be open for debate at Wednesday's meeting of the FDA's Arthritis Advisory Committee (AAC).